Halo Pharma, a CDMO specializing in drug product pharmaceutical development and manufacturing services, will become a stand-alone business as a result of the sale of the Noramco API and associated businesses to Siegfried. Halo Pharma was purchased by the Noramco Group from Cambrex in 2023. With the sale of the API related assets of the Noramco Group, Halo will serve as a dedicated platform for drug product CDMO services. Halo’s sterile CDMO business is expected to be online in the second h...